Airsculpt Technologies price to free cash flow AIRS

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Oct 23, 2026: 114×
4-year median: 46.4×
Against its 4-year history: 75th; percentile: 0 is its lowest day, 100 its highest
4-year range: 15.0× to 420×
Peer median: 11.8×

Airsculpt Technologies' price to free cash flow is 114× as of Oct 23, 2026.

That is above its 4-year median of 46.4×, higher than on 75% of days in the last 4 years.

Over that time it ranged from 15.0× in May 2024 to 420× in Nov 2024.

The median for 10 healthcare stocks of a similar size is 11.8×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	114×	40.0×	394×
2025	51.4×	51.4×	289×
2024	270×	15.0×	420×
2023	27.8×	18.3×	48.3×

Against its peers

Companies in Healthcare nearest Airsculpt Technologies' size, closest first, today.

Company	Price to free cash flow
AIRSAirsculpt Technologies	114×
ICCCImmucell	22.1×
KEQUKewaunee Scientific	8.7×
LFVNLifevantage	11.0×
SPROSpero Therapeutics	n/m
APTAlpha Pro Tech	9.7×
ATNMActinium Pharmaceuticals	n/m
NEPHNephros	n/m
PDEXPro DEX	29.5×
PLXProtalix BioTherapeutics	26.8×
NATRNatures Sunshine Products	11.8×
Peer median	11.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Airsculpt Technologies

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.